Bluebird Brings Gene Editing Tech To Kite’s TCR Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies hope to produce more potent and selective TCR therapies for HPV-associated cancers, sharing both expenses and profits, with Kite leading development in the US and bluebird in Europe.